Octreotide vs Lanreotide: Differences, Evidence & Safety

Octreotide and lanreotide are the two long-established somatostatin analogs, and clinicians routinely weigh one against the other. Both mimic the body's natural hormone "off switch" to suppress growth hormone and other secretions, both are used for acromegaly and neuroendocrine tumors, and both are given as long-acting monthly injections. The practical differences are mostly in formulation and delivery rather than in what they fundamentally do.

At a glance

	Octreotide	Lanreotide
Drug class	Somatostatin analog	Somatostatin analog
Brand names	Sandostatin, Sandostatin LAR	Somatuline Depot / Autogel
Main receptor	SSTR2 (and SSTR5)	SSTR2 (mainly)
Approved uses	Acromegaly, carcinoid syndrome, VIPoma, variceal bleeding	Acromegaly, gastroenteropancreatic neuroendocrine tumors
Long-acting form	Intramuscular depot (needs reconstitution)	Prefilled deep subcutaneous gel
Self-administration	LAR usually given by a professional	Autogel can be given at home by a trained caregiver
Landmark tumor trial	PROMID (midgut NETs)	CLARINET (enteropancreatic NETs)
Shared risks	Gallstones, GI effects, blood-sugar changes	Gallstones, GI effects, blood-sugar changes

Octreotide vs lanreotide for acromegaly

Acromegaly is where these two are most often weighed against each other, because both are standard medical therapy when surgery does not bring growth hormone and IGF-1 under control.

What the head-to-head studies found

This pairing has actually been compared directly, repeatedly, since the late 1990s — and the answer has been consistent: broadly similar biochemical control. Comparative studies in Clinical Endocrinology (1999, 2000), European Journal of Endocrinology (1999), and a later post-operative comparison in Pituitary (2012) each found the two agents comparable for controlling growth hormone and IGF-1, with no consistent winner. Every one of those papers is in the reference list below.

What actually predicts response

Response tracks how strongly the tumour expresses SSTR2, the receptor both drugs bind most avidly. Densely SSTR2-expressing tumours tend to respond well to either; sparsely granulated tumours with low SSTR2 expression tend to respond poorly to both. This is why someone who responds inadequately to one first-generation analog often responds inadequately to the other — and why the usual next step is not to swap between them but to change mechanism, for example to the broader-spectrum analog pasireotide or a growth hormone receptor antagonist.

One documented difference: the gallbladder

The class as a whole promotes gallstones by suppressing gallbladder contraction, and a 1999 study in European Journal of Endocrinology looked specifically at whether the two differ on this point, reporting differing effects on gallbladder motility. It is one of the few places where a concrete difference between them has been measured rather than assumed.

The head-to-head evidence, at a glance

Most pages comparing these two drugs cite nothing at all. The comparative literature genuinely exists, so here it is — what was studied, and what it found. Full citations are in the reference list below.

Study	Setting	What it found
Clin Endocrinol, 1999 & 2000	Acromegaly, direct comparison	Comparable control of growth hormone and IGF-1
Eur J Endocrinol, 1999	Chronic acromegaly treatment	Comparable efficacy; a separate paper reported differing effects on gallbladder motility
Pituitary, 2012	Post-operative acromegaly	Comparable as post-surgical medical therapy
J Gastrointest Oncol, 2019 (n=91)	GEP-NETs, octreotide → lanreotide transition	Median PFS about 23.7 months after transition; no material difference in adverse events between the two treatment periods. Ipsen-funded — see the note below.
Clin Transl Oncol, 2025	Long-term GEP-NET experience	Long-run outcomes with both agents in routine practice
Sci Rep, 2025	Pharmacovigilance, reported adverse events	Compared the adverse-event profiles of the two analogs in real-world reporting data
Endocrine, 2026	Network meta-analysis, glucose metabolism	Compared somatostatin analogs on their effects on blood sugar

A note on who funds the research. The 2019 transition study was funded by Ipsen, which manufactures lanreotide, and included Ipsen employees among its authors; several co-authors disclose consulting relationships with Ipsen and with Novartis, which makes octreotide. That does not make its findings wrong, and it was published with those disclosures visible. But when two manufacturers compete in a small market, funding is worth knowing about — and the pages currently ranking for this comparison do not mention it.

Switching between octreotide and lanreotide

Switching between the two is routine, and the reasons are better documented than for most drug pairs.

Why people actually switch

A 2019 medical-record review of 91 patients with gastroenteropancreatic neuroendocrine tumours who moved from long-acting octreotide to lanreotide recorded the reasons. The most common single documented reason was progressive disease (22.0%), followed by formulary change (15.4%) and patient preference (9.9%); for a substantial share, no reason was documented at all.

Two things are worth drawing out of that. Clinical and practical reasons are both real drivers — formulary change and patient preference together account for a share comparable to disease progression, so a switch is often about coverage and convenience rather than the drug failing. But it would be wrong to say switching is only ever a lateral, lifestyle-driven move: progression was the leading recorded reason. At the same time, most patients in that study (57.1%) were not progressing when they transitioned.

What switching involves

A switch is timed so the first injection of the new drug falls as the previous depot's effect is waning, keeping hormone suppression continuous. IGF-1 and growth hormone (in acromegaly), or symptoms and imaging (in neuroendocrine tumours), are rechecked afterwards to confirm control has held, and the dose or interval is adjusted from there. In the 2019 review, adverse events were not materially different between the octreotide and lanreotide treatment periods — consistent with the class effects being shared.

On "conversion" between the two

A common search is for an octreotide-to-lanreotide conversion ratio. We do not publish dose conversions, and no reader should act on one found online. That is not evasiveness. Equivalent dosing is not fixed arithmetic: it depends on the dose and interval the patient was on, how well controlled they were, the tumour's receptor expression, organ function, and what the treating specialist is aiming for. Published equivalence guidance exists for clinicians and is applied case by case alongside biochemical monitoring — which is the only context in which it is safe to use.

If you are being switched, the conversion has been chosen for you by the prescriber, and the follow-up bloodwork is how it gets confirmed or corrected.

The formulation difference, and why it matters

The most concrete difference between these two drugs is not pharmacological at all. It is how each is manufactured into a month-long injection — and it is what patients actually notice.

Octreotide LAR uses biodegradable PLGA microspheres: the peptide is encapsulated in polymer particles that erode slowly in the muscle, releasing drug over weeks. The powder must be reconstituted with a diluent immediately before use and given as an intramuscular injection, which means preparation time and a trained professional.

Lanreotide Autogel takes a different route entirely. It is a supersaturated aqueous gel with essentially no polymer excipient — the peptide self-assembles into a depot on its own. It arrives in a prefilled syringe needing no reconstitution and is given as a deep subcutaneous injection, which is what makes home or caregiver administration feasible in many health systems.

That single engineering choice explains most of the practical differences in the table above: preparation time, who can give the injection, where it is given, and how much of a burden monthly treatment is across years of therapy. For a drug taken indefinitely, that is not a footnote.

How both compare with natural somatostatin

A related question worth answering directly: how do these analogs differ from somatostatin itself?

Natural somatostatin is a broad inhibitory hormone that suppresses growth hormone, insulin, glucagon, gastrin and much else. As a medicine it has one disabling flaw — a half-life of roughly two minutes. It would have to be given as a continuous infusion, and its very broad receptor activity would suppress far more than intended.

Octreotide and lanreotide are deliberate narrowings of that molecule. They keep the region responsible for the wanted effects, concentrate their activity on SSTR2 rather than all five receptor subtypes, and resist the enzymes that destroy the natural hormone. The result lasts hours in short-acting form and weeks as a depot. The analogs are not so much stronger than somatostatin as narrower and far more durable — which is what made a usable drug out of a hormone.

The bottom line

For most purposes octreotide and lanreotide are clinically interchangeable somatostatin analogs with overlapping uses and a shared side-effect profile dominated by gallstones and gastrointestinal effects. The choice often comes down to practicalities: lanreotide's prefilled deep-subcutaneous autogel can be more convenient and is easier to give outside a clinic, while octreotide has a short-acting form useful for testing tolerance and a broader set of labeled indications. Both are FDA-approved, prescription-only medicines used under specialist care.

Read the full guides: Octreotide · Lanreotide · New to peptides? what are peptides?

Frequently asked questions

Is octreotide or lanreotide better?

Neither is clearly superior for most uses — they are closely related somatostatin analogs with similar effectiveness and side effects. Lanreotide's prefilled subcutaneous autogel is often more convenient, while octreotide has a short-acting form and a broader set of approved indications. The choice is individualized.

What is the main difference between octreotide and lanreotide?

The biggest practical difference is delivery: octreotide's long-acting form is an intramuscular depot that needs reconstitution, while lanreotide comes as a prefilled deep-subcutaneous gel that can be given at home by a trained caregiver. Their mechanisms are very similar.

Are both octreotide and lanreotide FDA-approved?

Yes. Both are FDA-approved, prescription-only somatostatin analogs. Octreotide is approved for acromegaly, carcinoid syndrome, and VIPomas; lanreotide is approved for acromegaly and gastroenteropancreatic neuroendocrine tumors.

How do you switch from octreotide to lanreotide?

A specialist times the first lanreotide injection to when the previous octreotide depot is wearing off, so suppression stays continuous, then rechecks IGF-1, growth hormone or symptoms afterwards and adjusts. In a 2019 review of 91 patients making this transition, adverse events were not materially different between the two treatment periods.

Why do patients switch from octreotide to lanreotide?

In a 2019 medical-record review of 91 patients with gastroenteropancreatic neuroendocrine tumours, the most commonly documented reasons were progressive disease (22.0%), formulary change (15.4%) and patient preference (9.9%). Both clinical and practical reasons drive switching, though most patients in that study were not progressing at the time.

Is there an octreotide to lanreotide conversion?

Not a fixed arithmetic one that is safe to apply yourself. Equivalent dosing depends on the previous dose and interval, how well controlled the patient was, receptor expression and organ function. Clinicians apply published equivalence guidance case by case with follow-up bloodwork. We do not publish dose conversions.

Is lanreotide or octreotide better for acromegaly?

Direct comparisons since the late 1990s have consistently found similar control of growth hormone and IGF-1. Response tracks how strongly the tumour expresses the SSTR2 receptor, which both drugs target, so a poor responder to one is often a poor responder to the other. The practical differences are in formulation and delivery rather than efficacy.

Is Sandostatin the same as lanreotide?

No. Sandostatin is a brand of octreotide, made by Novartis; lanreotide is a different molecule sold as Somatuline Depot or Autogel, made by Ipsen. They are closely related somatostatin analogs with overlapping uses, but they are not the same drug and are not interchangeable without a prescriber's involvement.

References

Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.

More comparisons: Semaglutide vs Tirzepatide · Tirzepatide vs Retatrutide · Semaglutide vs Liraglutide · Semaglutide vs Retatrutide · All comparisons →

Octreotide vs Lanreotide